Nanoparticles are promising aids for drug delivery for previously challenging diseases, and many incurable ones. Curcumin (diferuloylmethane) is a pleiotropic molecule having various target molecules in the body. Despite its effects, curcumin-based drugs are not readily available in the market because of their low bioavailability. Although dietary intake and knowledge about the potential of curcumin are high in countries like India, studies indicate that the bioavailability problem still persists. However, administration of curcumin through inhalation has received little consideration. In this review we discuss the potential of curcumin, approaches made to overcome the bioavailability challenges, and novel approaches that could be applied in order to deliver curcumin in a pressurized metered dose inhaler (pMDI).
PadhyeS, ChavanD, PandeyS, DeshpandeJ, SwamyKV, SarkarFH. (2010) Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Reviews in Medicinal Chemistry, 10, 372–387.
2.
Vijaya SaradhiUV, LingY, WangJ, ChiuM, SchwartzEB, FuchsJR, ChanKK, LiuZ., (2010) A liquid chromatography-tandem mass spectrometric method for quantification of curcuminoids in cell medium and mouse plasma. Journal of Chromatography. B, Analytical Technologies in The Biomedical and Life Sciences, 878, 3045–3051.
KesserKC, GellerDE. (2009) New aerosol delivery devices for cystic fibrosis. Respiratory Care, 54, 754-767; discussion 767–758.
5.
BaileyMM, BerklandCJ. (2009) Nanoparticle formulations in pulmonary drug delivery. Medicinal Research Reviews, 29, 196–212.
6.
PatilJS, SarasijaS., (2012) Pulmonary drug delivery strategies: A concise, systematic review. Lung India, 29, 44–49.
7.
SelvamP, El-SherbinyIM, SmythHD. (2011) Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 24, 25–34.
8.
SinhaR, AndersonDE, McDonaldSS, GreenwaldP., (2003) Cancer risk and diet in India. Journal of Postgraduate Medicine, 49, 222–228.
9.
GuptaSC, PatchvaS, KohW, AggarwalBB. (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clinical and Experimental Pharmacology and Physiology, 39, 283–299.
10.
AnandP, ThomasSG, KunnumakkaraAB, SundaramC, HarikumarKB, SungB, TharakanST, MisraK, PriyadarsiniIK, RajasekharanKN, AggarwalBB. (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochemical Pharmacology, 76, 1590–1611.
11.
AliBH MH, NoureldayemSA, AmelO., BakheitAO, BlundenG. (2006) Some biological properties of curcumin: a review,. Natural Product Communications, 1, 509–521.
12.
AggarwalBB, HarikumarKB. (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The International Journal of Biochemistry and Cell Biology, 41, 40–59.
13.
ColeGM, TeterB, FrautschySA. (2007) Neuroprotective effects of curcumin. Advances in Experimental Medicine and Biology, 595, 197–212.
14.
GuptaSC, PrasadS, KimJH, PatchvaS, WebbLJ, PriyadarsiniIK, AggarwalBB. (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Natural Product Reports, 28, 1937–1955.
15.
ReuterS, GuptaSC, ParkB, GoelA, AggarwalBB. (2011) Epigenetic changes induced by curcumin and other natural compounds. Genes and Nutrition, 6, 93–108.
16.
ThangapazhamRL, SharmaA, MaheshwariRK. (2006) Multiple molecular targets in cancer chemoprevention by curcumin. The AAPS Journal, 8, E443-449.
17.
JurenkaJS. (2009) Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative Medicine Review, 14, 141–153.
18.
ChengAL, HsuCH, LinJK, HsuMM, HoYF, ShenTS, KoJY, LinJT, LinBR, Ming-ShiangW, YuHS, JeeSH, ChenGS, ChenTM, ChenCA, LaiMK, PuYS, PanMH, WangYJ, TsaiCC, HsiehCY. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Research, 21, 2895–2900.
19.
MimeaultM, BatraSK. (2011) Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chinese Medicine, 6, 31.
20.
HatcherH, PlanalpR, ChoJ, TortiFM, TortiSV. (2008) Curcumin: from ancient medicine to current clinical trials. Cellular and Molecular Life Sciences, 65, 1631–1652.
21.
LaoCD, RuffinMTt, NormolleD, HeathDD, MurraySI, BaileyJM, BoggsME, CrowellJ, RockCL, BrennerDE. (2006) Dose escalation of a curcuminoid formulation. BMC Complementary and Alternative Medicine, 6, 10.
22.
AsaiA, MiyazawaT., (2000) Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sciences, 67, 2785–2793.
23.
PanMH, HuangTM, LinJK. (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolism and Disposition, 27, 486–494.
24.
TamvakopoulosC, DimasK, SofianosZD, HatziantoniouS, HanZ, LiuZL, WycheJH, PantazisP., (2007) Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clinical Cancer Research, 13, 1269–1277.
25.
PfeifferE, HoehleSI, WalchSG, RiessA, SolyomAM, MetzlerM., (2007) Curcuminoids form reactive glucuronides in vitro. Journal of Agricultural and Food Chemistry, 55, 538–544.
26.
PunithavathiD, VenkatesanN, BabuM., (2000) Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology, 131, 169–172.
27.
VenkatesanN, PunithavathiV, ChandrakasanG., (1997) Curcumin protects bleomycin-induced lung injury in rats. Life Sciences, 61, PL51-58.
28.
XuM, DengB, ChowYL, ZhaoZZ, HuB., (2007) Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone. Journal of Ethnopharmacology, 112, 292–299.
29.
SmithMR, GangireddySR, NaralaVR, HogaboamCM, StandifordTJ, ChristensenPJ, KondapiAK, ReddyRC. (2010) Curcumin inhibits fibrosis- related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology, 298, L616-625.
30.
AraujoCC, LeonLL. (2001) Biological activities of Curcuma longa L. Memorias do Instituto Oswaldo Cruz, 96, 723–728.
31.
VareedSK, KakaralaM, RuffinMT, CrowellJA, NormolleDP, DjuricZ, BrennerDE. (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiology, Biomarkers and Prevention, 17, 1411–1417.
32.
DhillonN, AggarwalBB, NewmanRA, WolffRA, KunnumakkaraAB, AbbruzzeseJL, NgCS, BadmaevV, KurzrockR., (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical Cancer Research, 14, 4491–4499.
33.
GarceaG, BerryDP, JonesDJ, SinghR, DennisonAR, FarmerPB, SharmaRA, StewardWP, GescherAJ. (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiology, Biomarkers and Prevention, 14, 120–125.
34.
SharmaRA, EudenSA, PlattonSL, CookeDN, ShafayatA, HewittHR, MarczyloTH, MorganB, HemingwayD, PlummerSM, PirmohamedM, GescherAJ, StewardWP. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical Cancer Research, 10, 6847–6854.
35.
RaiP, JaiswalD, MehtaS, RaiD, SharmaB, WatalG., (2010) Effect of Curcuma longa Freeze Dried Rhizome Powder with Milk in Stz Induced Diabetic Rats. Indian Journal of Clinical Biochemistry, 25, 175–181.
36.
SehgalA, KumarM, JainM, DhawanDK. (2011) Piperine as an adjuvant increases the efficacy of curcumin in mitigating benzo(a)pyrene toxicity. Human and Experimental Toxicology, 31, 473–482.
37.
KurienBT, ScofieldRH. (2009) Oral administration of heat-solubilized curcumin for potentially increasing curcumin bioavailability in experimental animals. International Journal of Cancer, 125, 1992–1993.
38.
WangS, TanM, ZhongZ, ChenM, WangY., (2011) Nanotechnologies for Curcumin: An Ancient Puzzler Meets Modern Solutions. Journal of Nanomaterials, 2011, Article ID723178, 723178 pages.
39.
WuW, ShenJ, BanerjeeP, ZhouS., (2011) Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials, 32, 598–609.
40.
SasakiH, SunagawaY, TakahashiK, ImaizumiA, FukudaH, HashimotoT, WadaH, KatanasakaY, KakeyaH, FujitaM, HasegawaK, MorimotoT., (2011) Innovative preparation of curcumin for improved oral bioavailability. Biological and Pharmaceutical Bulletin, 34, 660–665.
41.
BishtS, FeldmannG, SoniS, RaviR, KarikarC, MaitraA, MaitraA., (2007) Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. Journal of Nanobiotechnology, 5, 18 pages.
42.
YadavVR, SureshS, DeviK, YadavS., (2009) Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and antiinflammatory activity in rat colitis model. AAPS PharmSciTech, 10, 752–762.
ZhangL, CaoF, DingB, LiQ, XiY, ZhaiG., (2011) Eudragit(R) S100 coated calcium pectinate microspheres of curcumin for colon targeting. Journal of Microencapsulation, 28, 659–667.
48.
SunD, ZhuangX, XiangX, LiuY, ZhangS, LiuC, BarnesS, GrizzleW, MillerD, ZhangHG. (2010) A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Molecular Therapy, 18, 1606–1614.
49.
GandapuU, ChaitanyaRK, KishoreG, ReddyRC, KondapiAK. (2011) Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PloS One, 6, e23388.
50.
RubinBK. (2010) Air and soul: the science and application of aerosol therapy. Respiratory Care, 55, 911–921.
51.
HessDR. (2008) Aerosol delivery devices in the treatment of asthma. Respiratory Care, 53, 699–723.
52.
SharmaA, SharmaS, KhullerGK. (2004) Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. The Journal of Antimicrobial Chemotherapy, 54, 761–766.
53.
DenyerJ, DycheT., (2010) The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 23 Suppl 1, S1-10.
54.
DiazKT, SkariaS, HarrisK, SolomitaM, LauS, BauerK, SmaldoneGC, CondosR., (2012) Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 25, 79–87.
55.
BrandP, SchulteM, WenckerM, HerpichCH, KleinG, HannaK, MeyerT., (2009) Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. The European Respiratory Journal, 34, 354–360.
56.
Semmler-BehnkeM, KreylingWG, SchulzH, TakenakaS, ButlerJP, HenryFS, TsudaA., (2012) Nanoparticle delivery in infant lungs. Proceedings of the National Academy of Sciences of the United States of America, 109, 5092–5097.
57.
El-SherbinyIM, SmythHD. (2012) Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Molecular Pharmaceutics, 9, 269–280.
